Opinion|Videos|November 28, 2023

NRG1 Fusion Testing Practices

Author(s)Teresa Macarulla, MD, PhD, Cindy Neuzillet, MD, PhD

Medical oncologists provide insights on the evolving molecular testing practices for NRG1 fusions.

Episodes in this series

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 1 Overview of NRG1 Fusions

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 2 NRG1 Fusion Testing Practices

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 3 Recent Data on Zenocutuzumab at ESMO 2023

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 4 Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 5 Clinical Pearls on Treating Patients with NRG1 Fusions

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 6 NRG1 Fusions in Lung and GI Cancers

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 7 Testing for NRG1 Fusions

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 8 Clinical Diagnosis of NRG1 Fusions in NSCLC

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 9 Ongoing Research of NRG1-Targeted Therapies

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 10 NRG1 Fusions in Pancreatic Cancer and Potential Role of Zenocutuzumab

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 11 Key Takeaways for the Treatment of NRG1 Fusion–Positive Malignancies

EP. 12 Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers

EP. 12 Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers

EP. 13 Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma

EP. 13 Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma

Educational support for this activity provided by Merus.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

ASTRO 2026 Preview: Pancreatic SBRT, Radiosurgery for Depression, and More

September 23rd, 2026

ASTRO 2026 Preview: Pancreatic SBRT, Radiosurgery for Depression, and More

Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.

PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer: © NawManusia - stock.adobe.com

September 22nd, 2026

PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer

A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.

KST-6051 Receives Fast Track Designation in KRAS-Mutant Solid Tumors: © barinovalena - stock.adobe.com

September 17th, 2026

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.

Trending on CancerNetwork

Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma

Etentamig Shows Superior Efficacy vs SOC in Relapsed/Refractory Myeloma